Domů › Rakovina ledvin (renální buněčný karcinom) › Texas › Houston
Klinické studie Rakovina ledvin (renální buněčný karcinom) v Houston, TX
35 studií pro Rakovina ledvin (renální buněčný karcinom) hledá účastníky v lokalitách v Houston a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Probíhá náborFáze 1
- NEO-811 Houston Site, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- UT MD Anderson Cancer Center, Houston
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Probíhá náborFáze 1/2
- University of Texas - MD Anderson Cancer Center, Houston
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Probíhá náborFáze 2
- UT MD Anderson Cancer Center, Houston
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Probíhá náborFáze 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Probíhá náborFáze 1/2
- MD Anderson Cancer Center, Houston
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Probíhá náborFáze 2
- M D Anderson Cancer Center, Houston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Probíhá náborFáze 1/2
- Texas Oncology - Gulf Coast, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology - Gulf Coast, Houston
- a dalších 1
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Probíhá náborFáze 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Probíhá náborFáze 1
- Md Anderson Cancer Center, Houston
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Probíhá náborFáze 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Methodist Willowbrook Hospital, Houston
- a dalších 1
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Probíhá náborFáze 2
- MD Anderson Cancer Center, Houston
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Probíhá náborFáze 2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- Research Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Houston Methodist Hospital, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Probíhá náborFáze 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Probíhá náborFáze 1
- The University of Texas M. D. Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Probíhá náborFáze 1
- MD Anderson Cancer Center, Houston
PET/MR for Characterization of Renal Masses (RMs)
Probíhá náborObservační studie
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Probíhá náborFáze 1/2
- MD Anderson Cancer Center, Houston
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Probíhá náborFáze 1
- UT MD Anderson, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Probíhá náborFáze 1
- M D Anderson Cancer Center, Houston
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Probíhá náborFáze 1/2
- MD Anderson Cancer Center, Houston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Probíhá náborFáze 1
- MD Anderson Cancer Center, Houston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Probíhá náborFáze 1
- University of Texas MD Anderson Cancer Center /ID# 252004, Houston
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Probíhá náborFáze 2
- MD Anderson Cancer Center, Houston
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Probíhá náborFáze 2
- M D Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Probíhá náborFáze 1/2
- MD Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Probíhá nábor
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Probíhá náborFáze 1/2
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
Probíhá náborFáze 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Probíhá náborFáze 1
- The University of Texas MD Anderson Cancer Center, Houston
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Probíhá náborFáze 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Probíhá náborFáze 2
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Studie Rakovina ledvin (renální buněčný karcinom) v jiných městech
- New York City, NY27 studií
- Dallas, TX23 studií
- Nashville, TN23 studií
- St. Louis, MO23 studií
- Los Angeles, CA20 studií
- Boston, MA16 studií
- Baldwin Park, CA16 studií
- Pittsburgh, PA15 studií
- Philadelphia, PA15 studií
- Queens, NY15 studií
- Cleveland, OH14 studií
- Rochester, MN14 studií
Další studie v Houston
- Nemalobuněčný plicní karcinom145 studií
- Rakovina prsu126 studií
- Rakovina (všechny typy)121 studií
- Metastatický karcinom104 studií
- Kolorektální karcinom102 studií
- Rakovina vaječníků89 studií
- Akutní myeloidní leukemie85 studií
- Rakovina plic78 studií
- Rakovina prostaty76 studií
- Rakovina endometria68 studií
- Rakovina slinivky břišní61 studií
- Melanom59 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.